From YC 2015 to JPM 2025: A decade of growth? ? 2015: A nervous single founder (José) takes the stage at Y Combinator's Demo Day, armed with some data, a PowerPoint deck and an ambitious vision to transform cancer treatment and outcomes for patients. The audience politely claps, some skeptical eyebrows are raised, and a few brave investors lean forward in their seats.? ? 2025: Sharing preclinical data of our CEACAM5 + MMAE lead asset at the J.P. Morgan Healthcare Conference. Presenting the potential of our CAPAC technology to industry leaders. The same visionary spark remains, but now it's backed by a decade of breakthrough innovations, and a team that's revolutionizing cancer care.? ? Some say the best measure of dreams isn't how big they start, but how far they've come. From that first pitch to 500 people in Mountain View to addressing healthcare's most influential figures in San Francisco, our journey spans more than just 10 years and 50 miles. It represents countless late nights, breakthrough moments, failed experiments that taught us resilience, and successful innovations that changed lives.? ? To our early believers who saw the potential, our dedicated team who built the impossible, and our partners who trusted us along the way: thank you for being part of this incredible journey.? ? Here's to the next decade of transforming outcomes for cancer patients.? ? #HowItStarted #HowItsGoing #Biotech #Cancer #Research #Innovation
关于我们
Shasqi is a biotech company whose mission is to revolutionize cancer treatment with click chemistry, a 2022 Nobel Prize winning technology. Our unique CAPAC? (Click Activated Protodrugs Against Cancer) platform uses click chemistry to target high doses of cancer drugs directly to the site of the tumor while minimizing toxicity to healthy cells, potentially improving the therapeutic index. Shasqi has developed an expansive and diverse library of antibody-mediated tumor-targeting agents and cancer therapeutic payloads. These are decoupled from each other and reunited at the site of the tumor via a click chemistry reaction. We are the first company to use click chemistry in humans. For more information, visit us at www.shasqi.com
- 网站
-
https://www.shasqi.com
Shasqi的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- San Francisco，California
- 类型
- 私人持股
- 创立
- 2015
- 领域
- Oncology和Click Chemistry
地点
-
主要
获取路线
US，California，San Francisco，94107
Shasqi员工
动态
-
Time flies when you work to develop cancer drugs with better outcomes for patients. Congratulations on your Shasqi anniversary George and Jesse. ?? We can't believe its been several years already, it feels like yesterday but we've accomplished so much already. Here's to many more years! ?? #ADC #biotech #innovation?
-
-
We couldn't have said it any better Travis! It's been amazing having you on the team this past year. Let's do better for patients together, cheers to many more years.
Returning from London and an energizing World ADC Event Series and celebrating my one-year anniversary with Shasqi – what a week. During my decade working on ADCs at Seagen and Merck, we faced a fundamental problem – how to overcome the off-target toxicities caused by catabolic activation by normal tissues. Only 1% of an ADC dose binds to the tumor; the remaining 99% is eliminated by normal cells. This process breaks the linker and exposures the normal cells and tissues to the toxic payload.? This off-target toxicity limits the dose of the drug that can be given, reducing patient benefit. It’s what is preventing ADCs from becoming the truly targeted, powerful treatments they have the potential to be. This is why I joined Shasqi.? Shasqi is solving the catabolic elimination problem by separating the binder from the payload, and reuniting them at the tumor using click chemistry. This overcomes the catabolic activation problem. The binder carries no payload, so anything that doesn’t bind the tumor is safely cleared. The protodrug is inert and is only activated when it clicks with the binder at the tumor. Anything that doesn’t click is safely cleared. This allows us to give more drug, hopefully increasing patient benefit.? Thanks to the incredible efforts of a stellar research team, including Sangeetha,Stefanie, Nathan, George, Masa, Jesse, and Tri-Hung, the progress we've made this year has been staggering.? Year one highlights:? - Generating impressive efficacy data with our lead asset, a CEACAM5 binder with MMAE payload? - Driving technological advancements with the platform including increasing the ‘Drug-Antibody Ratio (DAR)’ by adding more click chemistry components to the binder. As with ADCs, this increases the amount of drug that can be activated at the tumor. Unlike ADCs, this increase at the tumor does NOT come with an increase in off-target toxicity.?? - Expanding into the Radioligand Therapy (RLT) space? - Advancing business development discussions with partners interested in the potential of our technology It’s been an intense year, but I wouldn’t be anywhere else.? I’m so excited by what this technology can do, and this excitement grows with each new piece of data we generate – I’m not being hyperbolic when I say that Shasqi’s technology can truly be transformative for cancer outcomes.? My motivation has always been to do better for patients. I believe that with Shasqi’s technology we can do just that.? #ADC #WorldADCLondon #biotech #innovation
-
-
For International Women's Day, our Head of Comms,Sadie Whittaker, Ph.D., sat down with Director of in Vivo Biology, Sangeetha Srinivasan, Ph.D. and Scientist, Stefanie Wagner to discuss what advice would she have for women looking to advance into a leadership position? Watch their conversation to hear the valuable insights and practical wisdom. What advice would you add? Share below! ?? #InternationalWomensDay #WomenInScience #LeadershipInSTEM
-
The?Shasqi team, José M. Mejía Oneto and Travis Biechele?had a fabulous time in the Big Smoke this week at #WorldADC. Here are 3 highlights from our time in London: 1) Jamie Rich gave a fabulous presentation highlighting the fact that increasing linker stability results in the emergence of unexpected toxicities. 2) Networking with leaders in the targeted therapy space. It was great to have an opportunity to discuss our CAPAC platform and answer insightful questions from colleagues. 3) Exploring the sights of London - Jose can't pass up a good Big Ben photo, and Travis (having never been to London before) had to be reminded that the iconic red phone boxes are generally found outside, and don’t usually include champagne. ?? #WorldADC #ADC #london #innovation
-
-
At World ADC London today, our VP of Research, Travis, presented data on pre-targeting with CAPAC, and how it can overcome off-target toxicities hampering the efficacy of ADCs. We also presented data from our lead asset, a CEACAM5 binder with an MMAE payload. This poorly internalizing antigen is a perfect target from our platform, which doesn’t require internalization for protodrug activation. Didn't get a change to stop by the poster? Find the digital version here ?? https://lnkd.in/giz_uSuN #WorldADC #ADC #innovation
-
-
-
-
-
+4
-
-
Catch our team at Poster Session 2 from 10:30am - 11:30am GMT, we’ll be at poster number 29.?? ? Not a morning person? Join Travis' speaking session at 2pm GMT on the Clinical Lessons track! ? #ADC #WorldADCLondon #innovation #biotech
-
-
Shasqi转发了
#London calling! ???? ? ? Excited to be back in this city for the World ADC Event Series. Still confused about the drivers on the other side of the cab though. At least they still have a driver, compared to San Francisco during JPM...? ? I'm genuinely looking forward to connecting with old and new friends and colleagues in the ADC space, and hearing what everyone's been working on. These conferences are where some of our best collaborations begin. ? If you're around on Wednesday, March 5th at 2PM GMT, come check out my session where I'll be sharing our best learning of Shasqi's SQ3370 clinical program and how it shaped the future of tumor targeted therapies with CAPAC.? ? Oh, and a mental note to look RIGHT before crossing the street.??? ?? #WorldADCLondon #ADC #biotech #innovation
-
-
Our VP of Research, Travis Biechele is headed out to London to the World ADC Event Series. Catch our session on Wednesday 5th at 2pm GMT. We’ll also be sharing our data during Poster Session 2 from 10:30 - 11:30am on Wednesday 5th, poster number 29.? ? #ADC #WorldADCLondon #biotech #innovation
-
-
This March, we recognize Colorectal Cancer Awareness Month and the great work the Colorectal Cancer Alliance does.? ? Shasqi is committed to developing innovative treatments that offer hope to patients facing this challenging diagnosis. Colorectal cancer is the third most common cancer worldwide.? ? Together, we can make progress against colorectal cancer through awareness, research, and groundbreaking therapies.? ? #ColorectalCancerAwarenessMonth #biotech #oncology #innovation?
-